Gender-affirming hormonal therapies are a critical component of the care of transgender individuals. Transgender people are commonly prescribed estrogen or testosterone to promote male-to-female or female-to-male transitions and to preserve gender-specific characteristics long-term. However, some exogenous hormones, especially certain estrogen preparations, are an established risk factor of thrombosis. As the number of individuals seeking gender-based care is rising, there is an urgent need to identify and characterize the mechanisms underlying hormone-associated thrombosis and incorporate this information into clinical algorithms for diagnosis and management. Herein, we discuss historical evidence on the incidence of thrombosis and changes in plasma composition in transgender and cisgender cohorts. We present 3 case studies to demonstrate knowledge gaps in thrombosis risk stratification and prediction tools. We also present data from coagulation and fibrinolysis assays and discuss how information from these kinds of assays may be used to help guide the clinical management of transgender individuals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562871 | PMC |
| http://dx.doi.org/10.1016/j.rpth.2023.102197 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibrin film on clots is increased by haematocrit but reduced by inflammation: implications for platelets and fibrinolysis.
J Thromb Haemost
January 2025
Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Background: Blood clot formation, triggered by vascular injury, is crucial for haemostasis and thrombosis. Blood clots are composed mainly of fibrin fibres, platelets and red blood cells (RBCs). Recent studies show that clot surface also develops a fibrin film, which provides protection against wound infection and retains components such as RBCs within the clot.
View Article and Find Full Text PDFThe dynamics of thrombolysis over time in acute immunologic reactions.
Sci Rep
January 2025
Department of Emergency Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Article Synopsis
- Allergic reactions and angioedema are significant conditions in emergency care, affecting patient management.
- A study evaluated maximum lysis (ML) using thromboelastometry in patients with immunologic reactions, measuring ML at admission and two hours later.
- Results showed that patients still experiencing symptoms after two hours had higher ML than those who were asymptomatic, indicating a potential link between symptom persistence and changes in ML.
Prolonged prothrombin time in hyperemesis gravidarum as an indicator of vitamin K deficiency.
J Obstet Gynaecol Res
January 2025
Department of Obstetrics and Gynecology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Article Synopsis
- The study investigates the impact of maternal vitamin K deficiency on fetal health, specifically in patients with severe hyperemesis gravidarum.
- Researchers compared coagulation factors in hyperemesis patients with those undergoing other procedures and found significant changes, particularly in prothrombin time.
- Timely vitamin K supplementation can normalize coagulation levels, potentially preventing serious fetal complications related to vitamin K deficiency.
Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study.
RMD Open
December 2024
Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands
Objectives: To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).
Methods: Patients with newly diagnosed RA started methotrexate and were randomised to additional conventional treatment, certolizumab pegol, abatacept or tocilizumab. Several biomarkers for haemostasis were analysed including parameters of the two global haemostatic assays-overall haemostatic potential (OHP) and endogenous thrombin potential (ETP), as well as single haemostatic factors-fibrinogen, prothrombin fragment 1+2 (F1+2), D-dimer, thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (CLT) in 24 patients at baseline, 12 and 24 weeks after the start of the treatment.
Elevated tissue factor pathway inhibitor is associated with intracerebral haemorrhage of unknown cause in young adults.
Neurol Neurochir Pol
December 2024
Department of Thromboembolic Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Clinical Rationale For Study: We have reported that intracerebral haemorrhage (ICH) of unknown cause at a young age is associated with lower prothrombin and factor VII and higher antithrombin activity, along with the formation of looser fibrin networks displaying enhanced lysability. Patients with mild-to-moderate bleeding of unknown cause have elevated levels of free plasma tissue factor pathway inhibitor alpha (fTFPIα), inhibiting the tissue factor-factor VII complex and prothrombinase.
Aim Of Study: We hypothesised that patients with an intracerebral haemorrhage (ICH) of unknown cause may also exhibit higher fTFPIα.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!